Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population
M Salmani, B Ghaderi, A Fotoohi… - Cancer Chemotherapy …, 2022 - Springer
Purpose Fluoropyrimidines, the major chemotherapeutic agents in various malignancies
treatment, are metabolized by dihydropyrimidine dehydrogenase (DPD). DPD deficiency …
treatment, are metabolized by dihydropyrimidine dehydrogenase (DPD). DPD deficiency …
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience
C Jolivet, R Nassabein, D Soulières, X Weng… - The …, 2021 - academic.oup.com
Background Fluoropyrimidines are used in chemotherapy combinations for multiple cancers.
Deficient dihydropyrimidine dehydrogenase activity can lead to severe life‐threatening …
Deficient dihydropyrimidine dehydrogenase activity can lead to severe life‐threatening …
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased …
CW Ockeloen, A Raaijmakers… - Journal of Oncology …, 2023 - journals.sagepub.com
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
[HTML][HTML] Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population
RB Fredj, E Gross, L Chouchen, F B'Chir… - Comptes rendus …, 2007 - Elsevier
Dihydropyrimidine dehydrogenase enzyme (DPD) deficiency is a pharmacogenetic
syndrome leading to severe side-effects in patients receiving therapies containing the …
syndrome leading to severe side-effects in patients receiving therapies containing the …
[HTML][HTML] Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report
D Mukherji, SA Massih, A Tfayli, M Kanso… - Journal of Medical Case …, 2019 - Springer
Background Dihydropyrimidine dehydrogenase deficiency secondary to polymorphisms in
the DPYD gene can lead to significant toxicity associated with the administration of …
the DPYD gene can lead to significant toxicity associated with the administration of …
Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
LM Henricks, LN van Merendonk… - … Journal of Cancer, 2019 - Wiley Online Library
Carriers of the genetic DPYD* 2A variant, resulting in dihydropyrimidine dehydrogenase
deficiency, are at significantly increased risk of developing severe fluoropyrimidine …
deficiency, are at significantly increased risk of developing severe fluoropyrimidine …
[HTML][HTML] The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
F Iachetta, C Bonelli, A Romagnani, R Zamponi… - British Journal of …, 2019 - nature.com
Background Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in
severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the …
severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the …
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients
A Loganayagam, M Arenas-Hernandez… - Cancer chemotherapy …, 2010 - Springer
Purpose The fluoropyrimidines have been extensively used for almost five decade
worldwide for the treatment of solid cancers. However, severe toxicity is a major clinical …
worldwide for the treatment of solid cancers. However, severe toxicity is a major clinical …
High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro) pyrimidine catabolism
E Gross, K Seck, S Neubauer… - International …, 2003 - spandidos-publications.com
Dihydropyrimidine dehydrogenase (DPD) is the first and rate-limiting enzyme in the
degradation of pyrimidines and pyrimidine base analogs including the anticancer drugs 5 …
degradation of pyrimidines and pyrimidine base analogs including the anticancer drugs 5 …
Implementing DPYD* 2A genotyping in clinical practice, the Quebec experience.
C Jolivet, C Amireault, JPM Ayoub, P Beauregard… - 2019 - ascopubs.org
650 Background: Fluoropyrimidines (FU) are part of chemotherapy combinations for multiple
gastrointestinal cancers. Deficient dihydropyrimidine deshydrogenase (DPD) activity can …
gastrointestinal cancers. Deficient dihydropyrimidine deshydrogenase (DPD) activity can …